

## **Affitech A/S to be reported to the police by the DSFA according to the Danish law on securities trading and article 6 in the declaration on issuers obligations to inform**

**Copenhagen and Oslo, 17<sup>th</sup> September, 2010**

Affitech A/S, (NASDAQ OMX: AFFI), the antibody medicines company, today announced that the Danish Financial Supervisory Authority will report the Company to the police for five occasions of violations of the flagging rules for major shareholders possessions according to the Danish law on securities trading article and for lack of announcements on capital raise in June and July 2009 according to article 6 of the declaration on share issuing.

The five occasions of violations of the flagging rules refer to one event; which is the combination of Affitech AS and Pharmexa A/S in May 2009. The two article 6 violations also refer to the combination of the two companies and the corresponding capital increase in July 2009.

In the consultative procedure Affitech A/S has stated that the Company acknowledges that it has complied too late with formal obligations. The Company has further stated that the information on the capital raise was public information referring to announcements containing direct information on the capital raise from June 19<sup>th</sup> 2009 (changed ownership), June 30<sup>th</sup> 2009 (prospectus) and August 25<sup>th</sup> 2009 (quarterly report) as well as later announcements and the annual report of 2009. Affitech further issued a formal release on the capital raise in 2009 in April 2010 as requested by the Danish Financial Supervisory Authority.

**For more information please contact Affitech A/S:**

*Martin Welschhof, Managing Director*

*Tel # +47 95 12 81 37*

*Randi Krogsgaard, Corporate Communications*

*Tel # +45 2320 1001, e-mail: [ir@affitech.com](mailto:ir@affitech.com)*

### **About Affitech**

**Affitech AS** is a publicly traded (NASDAQ OMX Copenhagen) human therapeutic antibody company headquartered in Copenhagen, Denmark with R&D facilities in Oslo, Norway. The company utilizes a range of proprietary antibody technologies for the discovery of fully human antibodies for application in oncology, inflammation and other disease areas. CBAS™ (Cell Based Antibody Selection) is Affitech's premier discovery engine for the isolation of lead antibodies to cell surface molecules in situ. Several of the Company's proprietary product candidates were generated by CBAS™. Further information is available at [www.affitech.com](http://www.affitech.com).

**Disclaimer**

*This news release contains forward-looking statements and forecasts based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on results of the financial condition and operations of Affitech A/S. There are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forecasts. These factors include, among other things, risks associated with technological development, the risk that research & development will not yield new products that achieve commercial success, the impact of competition, the ability to transact viable and profitable commercial deals, the risk of non-approval of patents not yet granted, and difficulties of obtaining relevant governmental approvals for new products.*

*No expressed or implied representations or warranties are given concerning Affitech A/S or the accuracy or completeness of the information provided herein, and no claims shall be made by the recipient of this news release by virtue of the information contained herein.*